BIRC5 and synovial sarcoma: Because YM155 is an effective pro-apoptotic compound, it has been difficult to determine if survivin expression is a direct effect of the drug on epigenetic regulation of the Birc5 promoter or if it is a secondary consequence of activating other pro-apoptotic pathways in synovial sarcoma.